A new study has assessed the safety, tolerability, and effectiveness of extended-release guanfacine in children 6-17 years of age who have chronic tic disorders including Tourette's disorder.
List view / Grid view
Sarah Wills (Editorial Assistant: European Pharmaceutical Review)
Filter the results
The National Institute for Health and Care Excellence (NICE) in England has recommended Teva Pharmaceutical Industries Ltd’s Cinqaero (reslizumab) in its Final Appraisal Determination (FAD).